Dose-escalated radiation does not benefit patients with low-risk prostate cancer
the ONA take:
According to a new study published online ahead of print this week in JAMA Oncology, researchers have found that higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer. However, this association was not observed in patients with low-risk disease.
For the study, researchers analyzed data from 42,481 men with prostate cancer included in the National Cancer Database. Of those, 12,229 had low-risk disease, 16,714 had intermediate-risk disease, and 13,538 had high-risk prostate cancer. Patients were all diagnosed between 2004 and 2006 and received either standard-dose external-beam radiation therapy or dose-escalated radiation.
Results showed that higher dose radiotherapy was associated with increased survival in those with intermediate- and high-risk disease, but not in those with low-risk disease. The findings suggest that aggressive radiotherapy may not be beneficial in men with low-risk prostate cancer, adding to the evidence that watchful waiting or active surveillance may be better for these patients.
Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|